DI IASIO, Maria Grazia
 Distribuzione geografica
Continente #
NA - Nord America 2.744
EU - Europa 603
AS - Asia 495
SA - Sud America 9
OC - Oceania 2
AF - Africa 1
Totale 3.854
Nazione #
US - Stati Uniti d'America 2.743
CN - Cina 242
UA - Ucraina 179
SG - Singapore 138
DE - Germania 110
TR - Turchia 99
GB - Regno Unito 89
IT - Italia 82
SE - Svezia 48
FI - Finlandia 43
BE - Belgio 13
NL - Olanda 12
BR - Brasile 9
FR - Francia 8
RU - Federazione Russa 5
CZ - Repubblica Ceca 4
ID - Indonesia 4
IR - Iran 4
LT - Lituania 4
ES - Italia 3
AU - Australia 2
VN - Vietnam 2
AZ - Azerbaigian 1
GR - Grecia 1
HK - Hong Kong 1
IL - Israele 1
IN - India 1
JP - Giappone 1
MA - Marocco 1
MD - Moldavia 1
MX - Messico 1
PK - Pakistan 1
PL - Polonia 1
Totale 3.854
Città #
Fairfield 408
Woodbridge 385
Houston 226
Jacksonville 199
Ashburn 182
Chandler 169
Ann Arbor 140
Seattle 134
Wilmington 121
Santa Clara 120
Cambridge 104
Singapore 101
Izmir 66
Beijing 52
Nanjing 47
Princeton 40
San Diego 39
New York 32
Ferrara 31
Boardman 28
Shanghai 22
Falls Church 18
Nanchang 16
Milan 15
Changsha 13
Brussels 12
Shenyang 12
Hebei 11
Los Angeles 11
San Mateo 11
Tianjin 11
Dearborn 10
Helsinki 7
Jiaxing 7
London 7
Norwalk 7
Orange 7
Zhengzhou 7
Dronten 6
Jinan 6
Verona 6
Washington 6
Auburn Hills 5
Bremen 5
Kunming 5
Leawood 5
Mountain View 5
Munich 5
Augusta 4
Brno 4
Jakarta 4
Ardabil 3
Frankfurt am Main 3
Haikou 3
Monmouth Junction 3
Ningbo 3
Padova 3
Philadelphia 3
Alicante 2
Bologna 2
Des Moines 2
Dong Ket 2
Düsseldorf 2
Indiana 2
Prescot 2
Redmond 2
Tappahannock 2
Acton 1
Addison 1
Aracati 1
Araruama 1
Atlanta 1
Baku 1
Changchun 1
Chaozhou 1
Chisinau 1
Edinburgh 1
Fes 1
Fuzhou 1
Governador Valadares 1
Hangzhou 1
Hong Kong 1
Islington 1
Jardinópolis 1
Jinhua 1
Joinville 1
Karachi 1
Kilburn 1
Lanzhou 1
Logan 1
Marienheide 1
Mexico City 1
Monselice 1
New Bedfont 1
Paris 1
Paulista 1
Piscataway 1
Qinzhou 1
Redwood City 1
Rouen 1
Totale 2.966
Nome #
Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells 151
Nutlin-3 upregulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feed-back anti-apoptotic mechanism 133
The Sorafenib plus Nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of the FLT3 and p53 status 132
TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release 129
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) 122
Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells 120
Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells 120
Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70 117
Molecular bases of type II protein S deficiency: the I203-D204 deletion in the EGF4 domain alters GLA domain function 113
Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells 113
Mutation pattern in clinically asymptomatic coagulation factor VII deficiency 113
HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: A potential molecular mechanism to escape TRAIL cytotoxicity 110
Mesenchymal stem cells-derived vascular smooth muscle cells release abundant levels of osteoprotegerin 108
Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glul02Lys) in the second EGF‐like domain 107
Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells 107
The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells 106
The oncogene DEK promotes leukemic cell survival and is downregulated by both nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells 104
The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies 102
null 100
Reduced expression of cell cycle-associated genes in B lymphocytes purified from the peripheral blood of early-stage B chronic lymphocytic leukaemia patients 100
TNFRSF11B (tumor necrosis factor receptor superfamily, member 11b) 99
null 98
null 98
null 97
SOCS1 is significantly up-regulated in Nutlin-3-treated p53 wild-type B chronic lymphocytic leukemia (BCLL) samples and shows an inverse correlation with miR-155 96
Refinement of the LOH region 1 at 11q23.1 deleted in human breast carcinomas and sublocalization of 11 expressed sequence tags within the refined region 96
Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells 93
null 89
Detection of new polymorphic markers in the factor V gene: Association with factor V levels in plasma 84
null 83
Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms 78
null 69
Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to Nutlin-3 induces a characteristic gene expression profile, which correlates with Nutlin-3-mediated cytotoxicity 69
TNFSF10 (tumor necrosis factor Ligand) surfamily,member 10) 62
Risk of venous thromboembolism and stroke associated with oral contraceptives. Role of congenital thrombophilias 55
null 55
The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia 43
C reactive protein down-regulates TNF-related apoptosis inducing ligand expression in human peripheral monocytes via an Egr-1 dependent pathway. 41
Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages 37
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women 33
miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. 31
Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype. 27
Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes 26
Nutlin-3 downregulates the expression of the Oncogene TCL1 in primary B Chronic Lymphocytic Leukemic cells. 22
Totale 3.888
Categoria #
all - tutte 17.825
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.825


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020389 0 0 0 0 0 0 80 93 70 80 53 13
2020/2021535 47 64 14 83 17 51 18 54 10 59 89 29
2021/2022449 12 60 27 23 22 20 33 22 12 27 52 139
2022/2023398 41 20 20 41 66 57 11 32 54 7 28 21
2023/2024149 23 13 7 3 6 29 8 17 1 4 2 36
2024/2025355 23 21 64 44 122 50 31 0 0 0 0 0
Totale 3.888